NCT03081598 - Study to Evaluate Safety, Efficacy of PBI-4050 & Its Effect on Relevant Biomarkers in T2DM Patients With Metabolic Syndrome | Biotech Hunter

Enrollment

104

Participants

Timeline

Start Date

May 29, 2017

Primary Completion Date

September 6, 2018

Study Completion Date

September 6, 2018

Conditions

Type 2 Diabetes MellitusMetabolic Syndrome

Interventions

DRUG

PBI-4050

Soft gelatine capsule containing 200 mg of the active ingredient per capsule

OTHER

Placebo

Placebo soft gelatine capsule

Trial Locations (11)

C-Health, Edmonton

Omnispec Clinical Research, Mirabel

LMC Clinical Research Inc., Barrie

C-health - C-endo Division, Calgary

Centre de recherche clinique de Laval, Laval

Institut de Recherches Cliniques de Montreal (IRCM), Montreal

LMC Clinical Research Inc., Montreal

Manna Research, Québec

Synergy Medical Clinic, Sherwood Park

Manna Research, Toronto

Manna Research, Vancouver